Generation Bio (GBIO) Competitors

Coya Therapeutics (NASDAQ:COYA) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.

Does the MarketBeat Community prefer COYA or GBIO?

Generation Bio received 23 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Coya Therapeutics an outperform vote while only 71.88% of users gave Generation Bio an outperform vote.

Company	Underperform	Outperform
Coya Therapeutics	Outperform Votes 23 95.83%	Underperform Votes 1 4.17%
Generation Bio	Outperform Votes 46 71.88%	Underperform Votes 18 28.13%

Do institutionals & insiders have more ownership in COYA or GBIO?

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 21.1% of Generation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has stronger valuation and earnings, COYA or GBIO?

Coya Therapeutics has higher earnings, but lower revenue than Generation Bio. Coya Therapeutics is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$3.55M	26.31	-$7.99M	-$0.98	-5.71
Generation Bio	$19.89M	1.27	-$126.61M	-$1.98	-0.19

Do analysts prefer COYA or GBIO?

Coya Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 204.06%. Generation Bio has a consensus target price of $7.33, suggesting a potential upside of 1,845.18%. Given Generation Bio's higher probable upside, analysts clearly believe Generation Bio is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Generation Bio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor COYA or GBIO?

In the previous week, Coya Therapeutics had 3 more articles in the media than Generation Bio. MarketBeat recorded 4 mentions for Coya Therapeutics and 1 mentions for Generation Bio. Coya Therapeutics' average media sentiment score of 0.90 beat Generation Bio's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generation Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, COYA or GBIO?

Coya Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.78, suggesting that its stock price is 178% more volatile than the S&P 500.

Is COYA or GBIO more profitable?

Coya Therapeutics has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Coya Therapeutics' return on equity of -31.63% beat Generation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	N/A	-31.63%	-27.76%
Generation Bio	-782.86%	-104.85%	-49.54%

Summary

Coya Therapeutics beats Generation Bio on 10 of the 17 factors compared between the two stocks.